EP0267676A3 - Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases - Google Patents

Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases Download PDF

Info

Publication number
EP0267676A3
EP0267676A3 EP87307977A EP87307977A EP0267676A3 EP 0267676 A3 EP0267676 A3 EP 0267676A3 EP 87307977 A EP87307977 A EP 87307977A EP 87307977 A EP87307977 A EP 87307977A EP 0267676 A3 EP0267676 A3 EP 0267676A3
Authority
EP
European Patent Office
Prior art keywords
treatment
oxypropyl
xanthine
butyl
peripheral vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP87307977A
Other languages
German (de)
French (fr)
Other versions
EP0267676A2 (en
Inventor
Dieter Angersbach
Charles David Nicholson
Joachim Göring
Brian Morgan
Jonanthan Robert Sanders Arch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Wuelfing GmbH and Co KG
Beecham Group PLC
Original Assignee
Beecham Wuelfing GmbH and Co KG
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Wuelfing GmbH and Co KG, Beecham Group PLC filed Critical Beecham Wuelfing GmbH and Co KG
Publication of EP0267676A2 publication Critical patent/EP0267676A2/en
Publication of EP0267676A3 publication Critical patent/EP0267676A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for the treatment of cerebral vascular and neuronal degenerative disorders associated with learning, memory and cognitive dysfunctions including cerebral senility, multi-infarct dementia and senile dementia of the Alzheimer type and/or peripheral vascular disease and/or proliferative skin disease in mammals, such as humans, which comprises administering to the mammal in need of such treatment an effective amount of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine or a pharmaceutically acceptable salt thereof.
EP87307977A 1986-09-11 1987-09-09 Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases Withdrawn EP0267676A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8621869 1986-09-11
GB868621869A GB8621869D0 (en) 1986-09-11 1986-09-11 Treatment

Publications (2)

Publication Number Publication Date
EP0267676A2 EP0267676A2 (en) 1988-05-18
EP0267676A3 true EP0267676A3 (en) 1990-04-04

Family

ID=10604006

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87307977A Withdrawn EP0267676A3 (en) 1986-09-11 1987-09-09 Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases

Country Status (4)

Country Link
US (1) US4784999A (en)
EP (1) EP0267676A3 (en)
JP (1) JPS6379832A (en)
GB (1) GB8621869D0 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5196429A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5196430A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
US5021422A (en) * 1989-06-08 1991-06-04 Senetek Plc Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins
GB8918297D0 (en) * 1989-08-10 1989-09-20 Beecham Group Plc Novel treatment
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
CA2109796C (en) * 1991-05-24 2004-04-27 James A. Bianco Modulation of cellular response to external stimuli
AU2229992A (en) 1991-07-05 1993-02-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Use of substituted pyridazines against dermatosis
US5762953A (en) * 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
US5919474A (en) * 1997-10-28 1999-07-06 Vivus, Inc. Transurethral administration of vasoactive agents to treat peripheral vascular disease, related vascular diseases, and vascular impotence associated therewith
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2756229A (en) * 1956-07-24 Xanthine derivatives
GB1417323A (en) * 1968-11-25 1975-12-10 Hoechst Ag Physiologically active xanthine compounds and compositions containing them
FR2387035A1 (en) * 1977-04-12 1978-11-10 Cassenne Lab Sa NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS
US4289776A (en) * 1973-06-16 1981-09-15 Hoechst Aktiengesellschaft Xanthine derivatives
EP0173038A1 (en) * 1984-08-02 1986-03-05 LechMetall Landsberg GmbH Pressure relief valve for a boiler of an apparatus for treating food by steam
EP0173039A2 (en) * 1984-07-19 1986-03-05 BEECHAM - WUELFING GmbH & Co. KG Use of xanthine and thioxanthine derivatives for the preparation of medicaments

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59665A0 (en) * 1979-04-05 1980-06-30 Wuelfing J Kg Xanthine derivatives,process for their preparation and their use in pharmaceutical compositions
US4225607A (en) * 1979-05-14 1980-09-30 Johann A. Wulfing Pharmaceutical composition containing a xanthine derivative

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2756229A (en) * 1956-07-24 Xanthine derivatives
GB1417323A (en) * 1968-11-25 1975-12-10 Hoechst Ag Physiologically active xanthine compounds and compositions containing them
US4289776A (en) * 1973-06-16 1981-09-15 Hoechst Aktiengesellschaft Xanthine derivatives
FR2387035A1 (en) * 1977-04-12 1978-11-10 Cassenne Lab Sa NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS
EP0173039A2 (en) * 1984-07-19 1986-03-05 BEECHAM - WUELFING GmbH & Co. KG Use of xanthine and thioxanthine derivatives for the preparation of medicaments
EP0173038A1 (en) * 1984-08-02 1986-03-05 LechMetall Landsberg GmbH Pressure relief valve for a boiler of an apparatus for treating food by steam

Also Published As

Publication number Publication date
GB8621869D0 (en) 1986-10-15
EP0267676A2 (en) 1988-05-18
JPS6379832A (en) 1988-04-09
US4784999A (en) 1988-11-15

Similar Documents

Publication Publication Date Title
EP0267676A3 (en) Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases
GB2207055B (en) Apparatus for use in the treatment of spinal disorders
McClure et al. The effects of sensory stimulatory treatment on an autistic child.
GB2208476B (en) Improvements in or relating to apparatus for use in the treatment of spinal disorders
LTIP919A (en) Drugs and process for preparing thereof
GB9119037D0 (en) Pharmaceutical product for the treatment of immunoregulatory disorders
EP0331620A3 (en) Agent for the treatment of parkinson's disease
RU94012366A (en) 2- (4-HYDROXYPYRIDINO) -1-ALKANOL DERIVATIVES, METHOD FOR PRODUCING, INTERMEDIATE PRODUCT, PHARMACEUTICAL COMPOSITION, TREATMENT METHOD
EP0616032A3 (en) Preventive or therapeutic agents for Alzheimer's disease, a screening method for Alzheimer's disease, and human tau-protein kinase.
IL86423A0 (en) Pharmaceutical compositions for the treatment of alzheimer's disease
DE69209414D1 (en) Preparations that promote brain activity
TW197423B (en)
EP0275668A3 (en) Use of ketone derivatives in the treatment of cognitive disorders
EP0304294A3 (en) Taliscanin and other aristolactams for treating neurological disorders, parkinson's disease, alzheimer disease and impotence
ZA906057B (en) 4-(n-substituted amino)-2-butynyl-1-ureas and thioureas and derivatives thereof as centrally acting muscarinic agents
EP0383171A3 (en) 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders
GB2204488B (en) Pharmaceutical compositions for the treatment or prophylaxis of skin disorders
EP0666745A4 (en) Diagnosis and therapy for parkinson's disease.
IE811612L (en) Thiazoles
AU603375B2 (en) Therapeutic agent for the treatment of disorders associated with cerebral ischemia
AU1012588A (en) Method of treatment of central nervous system diseases such as alzheimer's disease and parkinson's disease and method of diagnosing alzheimer's disease
AU608865B2 (en) Treatment of cerebral disorders
HU903776D0 (en) Process for the production of pharmaceutical preparations for treating the diseases of the central nervous system and for the increasing of bloodstream in the cerebrum
Rosse et al. Motor impersistence mistaken for uncooperativeness in a patient with right-brain damage.
Van Mierlo Open pilot trial of pimozide in patients suffering from psychic stress.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE CH DE FR GB IT LI NL

17P Request for examination filed

Effective date: 19881201

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): BE CH DE FR GB IT LI NL

17Q First examination report despatched

Effective date: 19910726

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19941012

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GOERING, JOACHIM

Inventor name: ARCH, JONANTHAN ROBERT SANDERS

Inventor name: NICHOLSON, CHARLES DAVID

Inventor name: MORGAN, BRIAN

Inventor name: ANGERSBACH, DIETER